Overview

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2031-05-09

Target enrollment:

Participant gender:

Summary

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Fulvestrant
Letrozole